The Convergence of FemTech and Personalised Medicine in Women's Health

This report examines the intersection of FemTech and personalised medicine, analysing how digital health innovations are reshaping the landscape of women's health. It explores the evolution of FemTech from consumer-focused applications to clinically integrated solutions, the persistent data gap in women's health research and the challenges of generating robust real-world evidence.

Gain insights into strategies for integrating digital technologies with traditional pharmaceutical treatments, the importance of inclusive clinical trial design and the critical role of partnerships between pharmaceutical companies and FemTech startups. This report also addresses the commercial and regulatory considerations necessary for advancing innovation and highlights the broader economic and societal impact of improving women's health outcomes through collaborative, data-driven approaches.

Key Questions Answered:

• 1. How is FemTech evolving and being integrated into mainstream healthcare?
• 2. What factors contribute to the women's health data gap, and how can it be addressed?
• 3. How can digital technologies complement traditional pharmaceutical treatments in women's health?
• 4. What are the challenges and opportunities for partnerships between pharmaceutical companies and FemTech startups?
• 5. How can pharma and FemTech generate more robust real-world evidence for women's health?
• 6. What are the barriers to investment and innovation in FemTech, and how can they be overcome?
• 7. How can clinical trials become more inclusive of women, including pregnant and breastfeeding populations?
• 8. What models and strategies ensure successful collaboration between pharma and FemTech?
• 9. How can digital tools be designed to improve adherence and personalise care for women?
• 10. What is the future impact of FemTech on women's health outcomes and the broader healthcare ecosystem?

Key Companies:

Partial List of Participating Experts:

• Digital Health Implementation Lead R&D, Evinova
• General Manager UK operations, IBSA UK
• CEO, Theramex
• Global Head of UCB's Women of Childbearing Age Program, UCB

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.